KISQALI® (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Manufacturer's Website: Kisqali

Average retail cost: $2,800/month

Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dosed combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor... Wikipedia

Manufacturer's Website: Inqovi

Average retail cost: $7,850/month

Trifluridine/tipiracil (trade name Lonsurf) is a combination drug for the treatment of metastatic colorectal cancer. It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor. Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of trifluridine...Wikipedia

Manufacturer's Website: Lonsurf

Average retail cost: $12,150/month

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Manufacturer's Website: Vyxeos

Average retail cost: *

* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.